Search Results for NS0-004 Valid Learning Materials 🥌 Latest NS0-004 Exam Objectives ◀ Valid NS0-004 Exam Guide 🤸 Search for ▛ NS0-004 ▟ and easily obtain a free download on 「 www.pdfvce.com 」 🪓Latest NS0-004 Test Guide

Grant category: Research Grants in open competition

Year: 2023

Geography: Portugal

Mariana Oliveira’s project investigates the potential of using de-vitalized mesenchymal stromal cells (MSCs) as direct or indirect immunomodulatory or regenerative biomaterials for treatment of difficult-to-treat or chronic wounds.

The project aims at exploring MSCs as constituents of off-the-shelf easy-to-handle immunomodulatory biomaterials. The project focuses on using these materials to treat difficult-to-heal wounds, which may be chronic, or have proneness to become chronic if not properly treated.

Two treatment approaches will be explored using devitalized MSC aggregates through (i) their direct use as immunomodulatory and regenerative biomaterials capable of inducing healthy tissue deposition, or (ii) by their ability to promote localized immunosuppression. The latter approach targets skin allogeneic (i.e., non-self) engraftments in order to avoid or minimize systemic immunosuppressants intake, associated with proneness to infections, higher allograft rejection rate, and severe comorbidities.

The fact that no living cells are administered is expected to improve the predictability and safety of the devices when compared to other cell-based therapies.

The technology also eliminates risks related to possible cell migration to unwanted sites, or the occurrence of phenotypic changes after implantation (e.g., loss of regenerative features or differentiation into unwanted cell phenotypes, which may be particularly relevant for highly plastic cells like MSCs).

The hope is to develop efficient treatments for wound healing with minimal risk of side effects.

Grant category: Research Grants in open competition

Year: 2023

Geography: Spain

Allergic contact dermatitis (ACD) is a frequent skin condition associated with significant loss of quality of life. Finding specific biomarkers has emerged as a relevant challenge to improve the diagnosis of patients and unravel therapeutic alternatives.

Recent findings have highlighted the existence of allergen-specific transcriptomic fingerprinting (i.e., genetic patterns that enable unambiguous identification of entities – here allergens). However, to date only a few studies have been performed comparing a wide range of different allergens.

In the proposed project, Ana Giménez-Arnau, along with colleague David Pesqué, plans to make a gene expression analysis of biopsies from patch-induced ACD by methylisothiazolinone, diazolidinyl urea, nickel, isoeugenol and 2-hydroxi-ethylemetacrylate. Specifically, Ana Giménez-Arnau and her team will evaluate the presence of allergen-specific genetic fingerprinting, if common biomarkers between allergens can be identified, if there are transcriptomic changes depending on the biopsy timing and finally, they will correlate the results with the characteristics and intensity of inflammatory infiltrates and the level allergic reaction of the patch-induced ACD.

This prospective investigation will be based on recruitment of patients with ACD to the indicated allergens and includes two single patch tests containing the standard commercialized allergen and one single patch test with petrolatum (positive control) to be applied on day 1. Two biopsies will be taken on day 3 (one from the petrolatum patch and one from the first allergen patch). The final biopsy will be taken on day 5 from the remaining allergen patch.

Collectively, the project will provide insights to the genetic characteristics of allergic contact dermatitis and may provide a foundation for identifying common or allergen-specific treatment targets.

Grant category: Research Grants in open competition

Year: 2017

Geography: Denmark

Allergy is one of the world’s most common chronic conditions. It is caused by immunoreaction of the human body towards in principle otherwise harmless allergens, and the current method for allergy screening and monitoring is the skin prick test (SPT) where different allergens are introduced into the tested person’s skin.

This widely used method, however, is non-quantitative, relatively lengthy and patients might experience unpleasant reactions. Furthermore, clinical evaluation of the SPT requires physical assessment of visible changes of the skin due to local inflammation by an experienced health care professional.

In the supported PhD project, which involves collaboration between DTU Nanotech, the Allergy Clinic at Gentofte Hospital in Denmark, Malmö University in Sweden and the University of British Columbia in Canada, an allergy test based on a micropatch will be developed which may be both more efficient and accurate as well as less cumbersome.

The micropatch will introduce allergens to the skin with carbon micro needles and allow for instantaneous and quantitative monitoring of allergic reactions in the skin through in vivo electrochemical sensing of the histamine released from activated mast cells in the interstitial fluid.

If successful, the new micropatch-based test will provide for less unpleasant allergy tests, in particular relevant with children suffering from atopic dermatitis. Further, a successful micropatch test will be a valuable and effective mean to identify potential immunoreactions towards newly developed topical dermatological drugs.

The project is supported by the LEO Foundation, the Copenhagen Center for Health Technology – CACHET (www.cachet.dk) and DTU Nanotech.

Grant category: Research Grants in open competition

Year: 2012

Geography: Denmark

Psoriasis patients have increased risk of cardiovascular disease (CVD), which still carries high morbidity and mortality in western societies, and is increasing dramatically in the emerging economies.

Consequently, research directed at the interface between psoriasis and CVD, from the level of epidemiological studies to basic experimental research, is of paramount importance in order to improve overall care for psoriasis patients, as well as supporting the need to seek help to receive treatment.

A research project led by Dr Peter Riis Hansen, Gentofte Hospital, Department of Cardiology P, Denmark, will help to:

• Inform and motivate dermatologists to play a pivotal role in screening and helping patients with psoriasis to prevent an increased risk of CVD
• Motivate patients with psoriasis to, firstly, seek treatment and assessment of their CVD risk and, secondly, improve treatment of psoriasis to reduce the overall immune activation
• Establish a murine model of psoriasis and CVD that is suitable for mechanistic studies and preclinical drug evaluation
• Identify new markers of psoriasis and/or CVD activity that may be relevant for clinical use.

Publications:

Khalid U et al. Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care 2013;6:2404-7

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714512/

Khalid U et al. Psoriasis and risk of heart failure: a nation-wide cohort study. Eur J Heart Fail 2014;16:743-8

http://www.ncbi.nlm.nih.gov/pubmed/24903077

Khalid U et al. Sarcoidosis in patients with psoriasis: a population-based cohort study. PLoS ONE 2014;9(10)e109632

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186869

Khalid U et al. Increased risk of aortic valve stenosis in patients with psoriasis: A nation-wide cohort study. Eur Heart J 2015;36:2177-83

http://eurheartj.oxfordjournals.org/content/36/32/2177.long

Khalid U et al. A nationwide study of the risk of abdominal aortic aneurysms in patients with psoriasis

http://atvb.ahajournals.org/content/36/5/1043.long

Madsen M et al. Effects of TPA-induced experimental psoriasis-like skin inflammation in atherosclerosis-prone apoE knock-out mice. BMC Dermatology 2015

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940745